Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice

FEMS Immunology and Medical Microbiology

Volumn 66, Issue 3, 2012, Pages 436-444

  Jain Gupta, Neeta ^a   Contreras Rodriguez, Araceli ^b   Vemulapalli, Ramesh ^c   Witonsky, Sharon G ^a   Boyle, Stephen M ^a   Sriranganathan, Nammalwar ^a  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Brucella melitensis; Outer membrane vesicles; Pluronics; Vaccine

Indexed keywords

BRUCELLA OUTER MEMBRANE VESICLE VACCINE; BRUCELLA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; POLOXAMER; POLOXAMER P85; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BRUCELLOSIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFICACY; ELECTRON MICROSCOPY; FEMALE; IN VITRO STUDY; INFECTION PREVENTION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BRUCELLA MELITENSIS; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; EXOSOMES; FEMALE; IMMUNOGLOBULIN G; MACROPHAGES; MICE; MICE, INBRED BALB C; POLOXALENE; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SUBUNIT;

EID: 84869827363     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/1574-695X.12010     Document Type: Article

References (38)

1. Adone R, Francia M, Pistoia C, Petrucci P, Pesciaroli M & Pasquali P (2012) Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice. Vaccine 30: 3992-3995.
2. Allison AC & Byars NE (1986) An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 95: 157-168.
3. Asaad AM & Alqahtani JM (2012) Serological and molecular diagnosis of human brucellosis in Najran, Southwestern Saudi Arabia. J Infect Public Health 5: 189-194.
4. Avila-Calderon ED, Lopez-Merino A, Jain N, Peralta H, Lopez-Villegas EO, Sriranganathan N, Boyle SM, Witonsky S & Contreras Rodriguez A (2012) Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice. Clin Dev Immunol 2012: 352493.
5. Baldwin CL & Goenka R (2006) Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit Rev Immunol 26: 407-442.
6. Batrakova EV & Kabanov AV (2008) Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 130: 98-106.
7. Beveridge TJ (1999) Structures of Gram-negative cell walls and their derived membrane vesicles. J Bacteriol 181: 4725-4733.
8. Byars NE & Allison AC (1987) Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 5: 223-228.
9. Coffman RL, Sher A & Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
10. Collins BS (2011) Gram-negative outer membrane vesicles in vaccine development. Discov Med 12: 7-15.
11. Corbel MJ (1997) Brucellosis: an overview. Emerg Infect Dis 3: 213-221.
12. Delpino MV, Estein SM, Fossati CA, Baldi PC & Cassataro J (2007) Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 25: 6721-6729.
13. Gamazo C & Moriyon I (1987) Release of outer membrane fragments by exponentially growing Brucella melitensis cells. Infect Immun 55: 609-615.
14. Gamazo C, Winter AJ, Moriyon I, Riezu-Boj JI, Blasco JM & Diaz R (1989) Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis. Infect Immun 57: 1419-1426.
15. Gaymalov ZZ, Yang Z, Pisarev VM, Alakhov VY & Kabanov AV (2009) The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials 30: 1232-1245.
16. Grillo MJ, Blasco JM, Gorvel JP, Moriyon I & Moreno E (2012) What have we learned from brucellosis in the mouse model? Vet Res 43: 29.
17. Hunter R, Strickland F & Kezdy F (1981) The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J Immunol 127: 1244-1250.
18. Jagannath C, Emanuele MR & Hunter RL (1999) Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice. Antimicrob Agents Chemother 43: 2898-2903.
19. Jagannath C, Emanuele MR & Hunter RL (2000) Activity of poloxamer CRL-1072 against drug-sensitive and resistant strains of Mycobacterium tuberculosis in macrophages and in mice. Int J Antimicrob Agents 15: 55-63.
20. Jubier-Maurin V, Boigegrain RA, Cloeckaert A, Gross A, Alvarez-Martinez MT, Terraza A, Liautard J, Kohler S, Rouot B, Dornand J & Liautard JP (2001) Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. Infect Immun 69: 4823-4830.
21. Kabanov AV & Alakhov VY (2002) Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 19: 1-72.
22. Kabanov AV, Kozlov MY, Melik-Nubarov NS & Batrakova EV (2000) Relationship between pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes. Macromolecules 33: 3305-3313.
23. Kang ML, Jiang HL, Kang SG, Guo DD, Lee DY, Cho CS & Yoo HS (2007) Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 25: 4602-4610.
24. Katakam M & Banga AK (1997) Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharm Dev Technol 2: 143-149.
25. Kuehn MJ & Kesty NC (2005) Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev 19: 2645-2655.
26. Lapaque N, Takeuchi O, Corrales F, Akira S, Moriyon I, Howard JC & Gorvel JP (2006) Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides. Cell Microbiol 8: 401-413.
27. Limet J, Plommet AM, Dubray G & Plommet M (1987) Immunity conferred upon mice by anti-LPS monoclonal antibodies in murine brucellosis. Ann Inst Pasteur Immunol 138: 417-424.
28. Mallapragada SK & Narasimhan B (2008) Immunomodulatory biomaterials. Int J Pharm 364: 265-271.
29. Memish ZA & Balkhy HH (2004) Brucellosis and international travel. J Travel Med 11: 49-55.
30. Montaraz JA, Winter AJ, Hunter DM, Sowa BA, Wu AM & Adams LG (1986) Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies. Infect Immun 51: 961-963.
31. Moustafa D, Garg VK, Jain N, Sriranganathan N & Vemulapalli R (2011) Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge. Vaccine 29: 784-794.
32. Neudeck BL, Alford TD, Faith NG & Czuprynski CJ (2008) The poloxamer P85 is protective against Listeria monocytogenes invasion. Foodborne Pathog Dis 5: 859-865.
33. Pappas G, Akritidis N, Bosilkovski M & Tsianos E (2005) Brucellosis. N Engl J Med 352: 2325-2336.
34. Perkins SD, Smither SJ & Atkins HS (2010) Towards a Brucella vaccine for humans. FEMS Microbiol Rev 34: 379-394.
35. Snippe H, De Reuver MJ, Strickland F, Willers JM & Hunter RL (1981) Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int Arch Allergy Appl Immunol 65: 390-398.
36. Tamayo I, Irache JM, Mansilla C, Ochoa-Reparaz J, Lasarte JJ & Gamazo C (2010) Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin Vaccine Immunol 17: 1356-1362.
37. Vemulapalli R, Duncan AJ, Boyle SM, Sriranganathan N, Toth TE & Schurig GG (1998) Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51. Infect Immun 66: 5684-5691.
38. Wang PL & Johnston TP (1993) Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 47: 183-189.